| Summary: | 碩士 === 嘉南藥理大學 === 生物科技系 === 105 === Backgrounds: Oral Squamous Cell Carcinoma (OSCC) is one of the most prevalent cancers and ranks 6th most common malignancy worldwide. In Taiwan, oral cancer was the 4th most common cancer in males. Oral tongue squamous cell carcinoma (OTSCC) is the top 2 common form of oral cancer and represents 28.10% of oral cancer. OTSCC is known as an aggressive tumor with a propensity to metastasis, poorer locoregional control and a high recurrence rate. To date, there is no biomarker for diagnosis and treatment for OTSCC. Tumor surface protein is an ideal diagnostic biomarker and target for immunotherapy. The Receptor expression-enhancing protein 6 (REEP6) is a surfaced protein and highly expressed in many cancers. However, the expression level of REEP6 in OSCC has never been reported. We found that high REEP6 mRNA expression level is associated with poor prognosis in oral cancer through big data analysis with The Cancer Genome Atlas (TCGA) database analysis. Nevertheless, the association of REEP6 protein level with clinicopathological parameters and survival remains unknown. Therefore, the aim of this study was to investigate the effect of REEP6 protein expressjion on tumor progression and prognosis in patients with OTSCC.
Materials and Methods: The expression of REEP6 protein in tissue microarray (TMA) was dstermined by immunohistochemistry staining (IHC) . In the tissue microarray, there were 250 surgically resected tongue squamous cell carcinoma core ( two cores in each patient) , 201 tumor adjacent normal tissue cores (one core per patient ) with another 35 ventilated patients with normal uvula tissue cores (1 core per patient) .
Results: The results of immunohistochemical staining showed that the expression of REEP6 protein in tumor tissue and tumor adjacent tissues was significantly higher than that in uvula normal tissue (p = 0.05) . However, the expression of REEP6 was not significantly association with clinicopathological parameters and survival. Further, stratification analysis showed that high expression level of REEP6 in patients with small tumor (T1 / T2) had significantly poor disease-specific survival (DSS) (AHR = 1.90, p = 0.012). In patients with age ≦ 50 years (AHR = 1.87, p = 0.038) or tumors with small (T1 / T2) (AHR = 1.64, p = 0.043), high-expression level of REEP6 also had significantly worse disease-free survival (DFS).
Conclusion: The expression of REEP6 in OTSCC may be associated with tumorigenesis, and the high protein level of REEP6 was not associated with shorter disease-specific survival (DSS) and disease-free recurrence (Disease-free survival, DFS) except in those patients with tumor size and age <50 years.
|
|---|
